ID   S29A3_HUMAN             Reviewed;         475 AA.
AC   Q9BZD2; B2RB50; B4E2Z9; B7ZA37; Q0VAM9; Q5T465; Q7RTT8; Q8IVZ0;
AC   Q9BWI2; Q9NUS9;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   10-MAY-2017, entry version 132.
DE   RecName: Full=Equilibrative nucleoside transporter 3;
DE            Short=hENT3;
DE   AltName: Full=Solute carrier family 29 member 3;
GN   Name=SLC29A3; Synonyms=ENT3; ORFNames=UNQ717/PRO1380;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS PHE-158; ILE-239
RP   AND VAL-326.
RC   TISSUE=Placenta;
RX   PubMed=11396612; DOI=10.1080/09687680118799;
RA   Hyde R.J., Cass C.E., Young J.D., Baldwin S.A.;
RT   "The ENT family of eukaryote nucleoside and nucleobase transporters:
RT   recent advances in the investigation of structure/function
RT   relationships and the identification of novel isoforms.";
RL   Mol. Membr. Biol. 18:53-63(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12384580; DOI=10.1093/nar/gkf564;
RA   Sankar N., Machado J., Abdulla P., Hilliker A.J., Coe I.R.;
RT   "Comparative genomic analysis of equilibrative nucleoside transporters
RT   suggests conserved protein structure despite limited sequence
RT   identity.";
RL   Nucleic Acids Res. 30:4339-4350(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS PHE-158; ILE-239
RP   AND VAL-326.
RC   TISSUE=Intestine;
RA   Tse C.-M., Ward J.L., Toan S.-V., Leung G.P.H., To K.K.W.;
RT   "Expression of human equilibrative nucleoside transporter-3 confers
RT   cellular resistance to nucleoside drugs.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   GLY-18; ILE-239 AND VAL-326.
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND
RP   VARIANTS PHE-158; ILE-239 AND VAL-326.
RC   TISSUE=Placenta, Skin fibroblast, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   PHE-158; ILE-239 AND VAL-326.
RC   TISSUE=Eye, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF LEU-31 AND LEU-32.
RX   PubMed=15701636; DOI=10.1074/jbc.M414337200;
RA   Baldwin S.A., Yao S.Y.M., Hyde R.J., Ng A.M.L., Foppolo S., Barnes K.,
RA   Ritzel M.W.L., Cass C.E., Young J.D.;
RT   "Functional characterization of novel human and mouse equilibrative
RT   nucleoside transporters (hENT3 and mENT3) located in intracellular
RT   membranes.";
RL   J. Biol. Chem. 280:15880-15887(2005).
RN   [9]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [10]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF GLY-427, AND CHARACTERIZATION OF
RP   VARIANTS HLAS ARG-116; SER-427; ARG-437 AND ARG-449.
RX   PubMed=20595384; DOI=10.1074/jbc.M110.109199;
RA   Kang N., Jun A.H., Bhutia Y.D., Kannan N., Unadkat J.D.,
RA   Govindarajan R.;
RT   "Human equilibrative nucleoside transporter-3 (hENT3) spectrum
RT   disorder mutations impair nucleoside transport, protein localization,
RT   and stability.";
RL   J. Biol. Chem. 285:28343-28352(2010).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   VARIANTS HLAS SER-427 AND ARG-437.
RX   PubMed=18940313; DOI=10.1016/j.ajhg.2008.09.013;
RA   Molho-Pessach V., Lerer I., Abeliovich D., Agha Z., Abu Libdeh A.,
RA   Broshtilova V., Elpeleg O., Zlotogorski A.;
RT   "The H syndrome is caused by mutations in the nucleoside transporter
RT   hENT3.";
RL   Am. J. Hum. Genet. 83:529-534(2008).
RN   [13]
RP   VARIANTS HLAS ARG-116; ARG-437 AND ARG-449.
RX   PubMed=19336477; DOI=10.1093/hmg/ddp161;
RA   Cliffe S.T., Kramer J.M., Hussain K., Robben J.H., de Jong E.K.,
RA   de Brouwer A.P., Nibbeling E., Kamsteeg E.J., Wong M., Prendiville J.,
RA   James C., Padidela R., Becknell C., van Bokhoven H., Deen P.M.,
RA   Hennekam R.C., Lindeman R., Schenck A., Roscioli T., Buckley M.F.;
RT   "SLC29A3 gene is mutated in pigmented hypertrichosis with insulin-
RT   dependent diabetes mellitus syndrome and interacts with the insulin
RT   signaling pathway.";
RL   Hum. Mol. Genet. 18:2257-2265(2009).
RN   [14]
RP   VARIANTS HLAS CYS-134 AND ARG-437.
RX   PubMed=20199539; DOI=10.1111/j.1365-2133.2010.09653.x;
RA   Priya T.P., Philip N., Molho-Pessach V., Busa T., Dalal A.,
RA   Zlotogorski A.;
RT   "H syndrome: novel and recurrent mutations in SLC29A3.";
RL   Br. J. Dermatol. 162:1132-1134(2010).
RN   [15]
RP   VARIANTS HLAS SER-427 AND ARG-437.
RX   PubMed=20619369; DOI=10.1016/j.ejmg.2010.06.012;
RA   Spiegel R., Cliffe S.T., Buckley M.F., Crow Y.J., Urquhart J.,
RA   Horovitz Y., Tenenbaum-Rakover Y., Newman W.G., Donnai D.,
RA   Shalev S.A.;
RT   "Expanding the clinical spectrum of SLC29A3 gene defects.";
RL   Eur. J. Med. Genet. 53:309-313(2010).
RN   [16]
RP   VARIANTS HLAS ARG-184 AND ARG-437.
RX   PubMed=20399510; DOI=10.1016/j.ijporl.2010.03.053;
RA   Ramot Y., Sayama K., Sheffer R., Doviner V., Hiller N.,
RA   Kaufmann-Yehezkely M., Zlotogorski A.;
RT   "Early-onset sensorineural hearing loss is a prominent feature of H
RT   syndrome.";
RL   Int. J. Pediatr. Otorhinolaryngol. 74:825-827(2010).
RN   [17]
RP   VARIANTS HLAS TRP-363 AND GLN-363.
RX   PubMed=19889517; DOI=10.1016/j.jdermsci.2009.09.011;
RA   Molho-Pessach V., Suarez J., Perrin C., Chiaverini C., Doviner V.,
RA   Tristan-Clavijo E., Colmenero I., Giuliano F., Torrelo A.,
RA   Zlotogorski A.;
RT   "The H syndrome: two novel mutations affecting the same amino acid
RT   residue of hENT3.";
RL   J. Dermatol. Sci. 57:59-61(2010).
RN   [18]
RP   VARIANT HLAS ARG-437, AND VARIANTS VAL-163; PRO-281 AND MET-407.
RX   PubMed=20140240; DOI=10.1371/journal.pgen.1000833;
RA   Morgan N.V., Morris M.R., Cangul H., Gleeson D.,
RA   Straatman-Iwanowska A., Davies N., Keenan S., Pasha S., Rahman F.,
RA   Gentle D., Vreeswijk M.P., Devilee P., Knowles M.A., Ceylaner S.,
RA   Trembath R.C., Dalence C., Kismet E., Koseoglu V., Rossbach H.C.,
RA   Gissen P., Tannahill D., Maher E.R.;
RT   "Mutations in SLC29A3, encoding an equilibrative nucleoside
RT   transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad
RT   histiocytosis) and familial Rosai-Dorfman disease.";
RL   PLoS Genet. 6:E1000833-E1000833(2010).
RN   [19]
RP   VARIANT HLAS GLN-363.
RX   PubMed=21888995; DOI=10.1016/j.ejmg.2011.06.009;
RA   Jonard L., Couloigner V., Pierrot S., Louha M., Gherbi S.,
RA   Denoyelle F., Marlin S.;
RT   "Progressive hearing loss associated with a unique cervical node due
RT   to a homozygous SLC29A3 mutation: a very mild phenotype.";
RL   Eur. J. Med. Genet. 55:56-58(2012).
CC   -!- FUNCTION: Mediates both influx and efflux of nucleosides across
CC       the membrane (equilibrative transporter). Mediates transport of
CC       adenine, adenosine and uridine, as well as several nucleoside
CC       analog drugs, such as anticancer and antiviral agents, including
CC       cladribine, cordycepin, tubercidin and AZT. Does not transport
CC       hypoxanthine. {ECO:0000269|PubMed:15701636}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.86 mM for adenosine {ECO:0000269|PubMed:15701636};
CC         KM=2.02 mM for uridine {ECO:0000269|PubMed:15701636};
CC       pH dependence:
CC         Optimum pH is 5.5 for adenosine uptake.
CC         {ECO:0000269|PubMed:15701636};
CC   -!- INTERACTION:
CC       O43889-2:CREB3; NbExp=3; IntAct=EBI-12701374, EBI-625022;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein. Late
CC       endosome membrane. Lysosome membrane. Note=Observed in a punctate
CC       intracellular pattern showing partial colocalization with late
CC       endosomes/lysosomes. Not detected at the cell surface.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BZD2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BZD2-2; Sequence=VSP_037436;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed in both adult and fetal
CC       tissues. Highest levels in placenta, uterus, ovary, spleen, lymph
CC       node and bone marrow. Lowest levels in brain and heart.
CC       {ECO:0000269|PubMed:15701636}.
CC   -!- DISEASE: Histiocytosis-lymphadenopathy plus syndrome (HLAS)
CC       [MIM:602782]: A syndrome characterized by the combination of
CC       features from 2 or more of four histiocytic disorders, originally
CC       thought to be distinct: Faisalabad histiocytosis (FHC), sinus
CC       histiocytosis with massive lymphadenopathy (SHML), H syndrome, and
CC       pigmented hypertrichosis with insulin-dependent diabetes mellitus
CC       syndrome (PHID). FHC features include joint deformities,
CC       sensorineural hearing loss, and subsequent development of
CC       generalized lymphadenopathy and swellings in the eyelids that
CC       contain histiocytes. SHML causes lymph node enlargement in
CC       children frequently accompanied by fever, leukocytosis, elevated
CC       erythrocyte sedimentation rate, and polyclonal
CC       hypergammaglobulinemia. H syndrome is characterized by cutaneous
CC       hyperpigmentation and hypertrichosis, hepatosplenomegaly, heart
CC       anomalies, and hypogonadism; hearing loss is found in about half
CC       of patients. PHID is characterized by predominantly antibody-
CC       negative insulin-dependent diabetes mellitus associated with
CC       pigmented hypertrichosis and variable occurrence of other features
CC       of H syndrome. {ECO:0000269|PubMed:18940313,
CC       ECO:0000269|PubMed:19336477, ECO:0000269|PubMed:19889517,
CC       ECO:0000269|PubMed:20140240, ECO:0000269|PubMed:20199539,
CC       ECO:0000269|PubMed:20399510, ECO:0000269|PubMed:20595384,
CC       ECO:0000269|PubMed:20619369, ECO:0000269|PubMed:21888995}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the SLC29A/ENT transporter (TC 2.A.57)
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA92041.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF326987; AAK00958.1; -; mRNA.
DR   EMBL; BK000392; DAA00364.1; -; Genomic_DNA.
DR   EMBL; AY288928; AAP41133.1; -; mRNA.
DR   EMBL; AY358686; AAQ89049.1; -; mRNA.
DR   EMBL; AK002022; BAA92041.1; ALT_INIT; mRNA.
DR   EMBL; AK314497; BAG37097.1; -; mRNA.
DR   EMBL; AK304503; BAG65311.1; -; mRNA.
DR   EMBL; AK316152; BAH14523.1; -; mRNA.
DR   EMBL; AL359183; CAI13424.1; -; Genomic_DNA.
DR   EMBL; AL359384; CAI13424.1; JOINED; Genomic_DNA.
DR   EMBL; AL359384; CAI16088.1; -; Genomic_DNA.
DR   EMBL; AL359183; CAI16088.1; JOINED; Genomic_DNA.
DR   EMBL; BC000223; AAH00223.1; -; mRNA.
DR   EMBL; BC041575; AAH41575.1; -; mRNA.
DR   EMBL; BC120996; AAI20997.1; -; mRNA.
DR   EMBL; BC120997; AAI20998.1; -; mRNA.
DR   CCDS; CCDS7310.1; -. [Q9BZD2-1]
DR   RefSeq; NP_001167569.1; NM_001174098.1.
DR   RefSeq; NP_060814.4; NM_018344.5. [Q9BZD2-1]
DR   RefSeq; XP_016871866.1; XM_017016377.1. [Q9BZD2-2]
DR   UniGene; Hs.438419; -.
DR   ProteinModelPortal; Q9BZD2; -.
DR   IntAct; Q9BZD2; 1.
DR   STRING; 9606.ENSP00000362285; -.
DR   TCDB; 2.A.57.1.6; the equilibrative nucleoside transporter (ent) family.
DR   iPTMnet; Q9BZD2; -.
DR   PhosphoSitePlus; Q9BZD2; -.
DR   BioMuta; SLC29A3; -.
DR   DMDM; 313104188; -.
DR   EPD; Q9BZD2; -.
DR   MaxQB; Q9BZD2; -.
DR   PaxDb; Q9BZD2; -.
DR   PeptideAtlas; Q9BZD2; -.
DR   PRIDE; Q9BZD2; -.
DR   Ensembl; ENST00000373189; ENSP00000362285; ENSG00000198246. [Q9BZD2-1]
DR   GeneID; 55315; -.
DR   KEGG; hsa:55315; -.
DR   UCSC; uc001jrr.5; human. [Q9BZD2-1]
DR   CTD; 55315; -.
DR   DisGeNET; 55315; -.
DR   GeneCards; SLC29A3; -.
DR   H-InvDB; HIX0008903; -.
DR   HGNC; HGNC:23096; SLC29A3.
DR   HPA; HPA046085; -.
DR   HPA; HPA054976; -.
DR   HPA; HPA057905; -.
DR   MalaCards; SLC29A3; -.
DR   MIM; 602782; phenotype.
DR   MIM; 612373; gene.
DR   neXtProt; NX_Q9BZD2; -.
DR   OpenTargets; ENSG00000198246; -.
DR   Orphanet; 1782; Dysosteosclerosis.
DR   Orphanet; 168569; H syndrome.
DR   PharmGKB; PA134950750; -.
DR   eggNOG; KOG1479; Eukaryota.
DR   eggNOG; ENOG410Y3MT; LUCA.
DR   GeneTree; ENSGT00390000002232; -.
DR   HOVERGEN; HBG108444; -.
DR   InParanoid; Q9BZD2; -.
DR   KO; K15014; -.
DR   OMA; YYMRPVL; -.
DR   OrthoDB; EOG091G09WB; -.
DR   PhylomeDB; Q9BZD2; -.
DR   TreeFam; TF313950; -.
DR   Reactome; R-HSA-83936; Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane.
DR   ChiTaRS; SLC29A3; human.
DR   GenomeRNAi; 55315; -.
DR   PRO; PR:Q9BZD2; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000198246; -.
DR   CleanEx; HS_SLC29A3; -.
DR   Genevisible; Q9BZD2; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005765; C:lysosomal membrane; IDA:UniProtKB.
DR   GO; GO:0005337; F:nucleoside transmembrane transporter activity; TAS:Reactome.
DR   InterPro; IPR030193; ENT3.
DR   InterPro; IPR002259; Eqnu_transpt.
DR   PANTHER; PTHR10332; PTHR10332; 1.
DR   PANTHER; PTHR10332:SF50; PTHR10332:SF50; 1.
DR   Pfam; PF01733; Nucleoside_tran; 1.
DR   PIRSF; PIRSF016379; ENT; 1.
DR   PRINTS; PR01130; DERENTRNSPRT.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Disease mutation; Endosome;
KW   Glycoprotein; Lysosome; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN         1    475       Equilibrative nucleoside transporter 3.
FT                                /FTId=PRO_0000209343.
FT   TOPO_DOM      1     53       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     54     74       Helical. {ECO:0000255}.
FT   TOPO_DOM     75    105       Extracellular. {ECO:0000255}.
FT   TRANSMEM    106    126       Helical. {ECO:0000255}.
FT   TOPO_DOM    127    134       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    135    155       Helical. {ECO:0000255}.
FT   TOPO_DOM    156    162       Extracellular. {ECO:0000255}.
FT   TRANSMEM    163    183       Helical. {ECO:0000255}.
FT   TOPO_DOM    184    199       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    200    220       Helical. {ECO:0000255}.
FT   TOPO_DOM    221    230       Extracellular. {ECO:0000255}.
FT   TRANSMEM    231    251       Helical. {ECO:0000255}.
FT   TOPO_DOM    252    305       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    306    326       Helical. {ECO:0000255}.
FT   TOPO_DOM    327    337       Extracellular. {ECO:0000255}.
FT   TRANSMEM    338    358       Helical. {ECO:0000255}.
FT   TOPO_DOM    359    377       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    378    398       Helical. {ECO:0000255}.
FT   TOPO_DOM    399    415       Extracellular. {ECO:0000255}.
FT   TRANSMEM    416    436       Helical. {ECO:0000255}.
FT   TOPO_DOM    437    454       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    455    475       Helical. {ECO:0000255}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99P65}.
FT   MOD_RES      23     23       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     84     84       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1    146       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037436.
FT   VARIANT      18     18       R -> G (in dbSNP:rs2277257).
FT                                {ECO:0000269|PubMed:12975309}.
FT                                /FTId=VAR_018662.
FT   VARIANT     116    116       M -> R (in HLAS; partially retained in
FT                                the endoplasmic reticulum; results in
FT                                reduced nucleoside transport;
FT                                dbSNP:rs267607057).
FT                                {ECO:0000269|PubMed:19336477,
FT                                ECO:0000269|PubMed:20595384}.
FT                                /FTId=VAR_067801.
FT   VARIANT     134    134       R -> C (in HLAS).
FT                                {ECO:0000269|PubMed:20199539}.
FT                                /FTId=VAR_067802.
FT   VARIANT     158    158       S -> F (in dbSNP:rs780668).
FT                                {ECO:0000269|PubMed:11396612,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018663.
FT   VARIANT     163    163       G -> V (in dbSNP:rs143557881).
FT                                {ECO:0000269|PubMed:20140240}.
FT                                /FTId=VAR_067803.
FT   VARIANT     184    184       S -> R (in HLAS).
FT                                {ECO:0000269|PubMed:20399510}.
FT                                /FTId=VAR_067804.
FT   VARIANT     239    239       V -> I (in dbSNP:rs2252996).
FT                                {ECO:0000269|PubMed:11396612,
FT                                ECO:0000269|PubMed:12975309,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018664.
FT   VARIANT     281    281       L -> P (in dbSNP:rs79737301).
FT                                {ECO:0000269|PubMed:20140240}.
FT                                /FTId=VAR_067805.
FT   VARIANT     326    326       I -> V (in dbSNP:rs2487068).
FT                                {ECO:0000269|PubMed:11396612,
FT                                ECO:0000269|PubMed:12975309,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018665.
FT   VARIANT     363    363       R -> Q (in HLAS; dbSNP:rs387907066).
FT                                {ECO:0000269|PubMed:19889517,
FT                                ECO:0000269|PubMed:21888995}.
FT                                /FTId=VAR_067806.
FT   VARIANT     363    363       R -> W (in HLAS; dbSNP:rs387907067).
FT                                {ECO:0000269|PubMed:19889517}.
FT                                /FTId=VAR_067807.
FT   VARIANT     407    407       V -> M (in dbSNP:rs144517514).
FT                                {ECO:0000269|PubMed:20140240}.
FT                                /FTId=VAR_067808.
FT   VARIANT     427    427       G -> S (in HLAS; almost total loss of
FT                                nucleoside transport; dbSNP:rs121912583).
FT                                {ECO:0000269|PubMed:18940313,
FT                                ECO:0000269|PubMed:20595384,
FT                                ECO:0000269|PubMed:20619369}.
FT                                /FTId=VAR_057884.
FT   VARIANT     437    437       G -> R (in HLAS; results in reduced
FT                                nucleoside transport; dbSNP:rs121912584).
FT                                {ECO:0000269|PubMed:18940313,
FT                                ECO:0000269|PubMed:19336477,
FT                                ECO:0000269|PubMed:20140240,
FT                                ECO:0000269|PubMed:20199539,
FT                                ECO:0000269|PubMed:20399510,
FT                                ECO:0000269|PubMed:20595384,
FT                                ECO:0000269|PubMed:20619369}.
FT                                /FTId=VAR_057885.
FT   VARIANT     449    449       T -> R (in HLAS; results in reduced
FT                                nucleoside transport; dbSNP:rs267607058).
FT                                {ECO:0000269|PubMed:19336477,
FT                                ECO:0000269|PubMed:20595384}.
FT                                /FTId=VAR_067809.
FT   VARIANT     452    452       V -> E (in dbSNP:rs999940).
FT                                /FTId=VAR_018666.
FT   MUTAGEN      31     31       L->A: Localization at the cell surface;
FT                                when associated with A-32.
FT                                {ECO:0000269|PubMed:15701636}.
FT   MUTAGEN      32     32       L->A: Localization at the cell surface;
FT                                when associated with A-31.
FT                                {ECO:0000269|PubMed:15701636}.
FT   MUTAGEN     427    427       G->A,F,Y,T: Results in impaired
FT                                nucleoside transport.
FT                                {ECO:0000269|PubMed:20595384}.
FT   CONFLICT     32     32       L -> P (in Ref. 5; BAG37097).
FT                                {ECO:0000305}.
FT   CONFLICT    112    112       T -> A (in Ref. 5; BAA92041).
FT                                {ECO:0000305}.
FT   CONFLICT    306    306       A -> S (in Ref. 5; BAG65311).
FT                                {ECO:0000305}.
FT   CONFLICT    370    370       Q -> R (in Ref. 5; BAA92041).
FT                                {ECO:0000305}.
FT   CONFLICT    453    453       M -> I (in Ref. 5; BAG65311).
FT                                {ECO:0000305}.
SQ   SEQUENCE   475 AA;  51815 MW;  DBF0918ECA6D5A70 CRC64;
     MAVVSEDDFQ HSSNSTYRTT SSSLRADQEA LLEKLLDRPP PGLQRPEDRF CGTYIIFFSL
     GIGSLLPWNF FITAKEYWMF KLRNSSSPAT GEDPEGSDIL NYFESYLAVA STVPSMLCLV
     ANFLLVNRVA VHIRVLASLT VILAIFMVIT ALVKVDTSSW TRGFFAVTIV CMVILSGAST
     VFSSSIYGMT GSFPMRNSQA LISGGAMGGT VSAVASLVDL AASSDVRNSA LAFFLTATVF
     LVLCMGLYLL LSRLEYARYY MRPVLAAHVF SGEEELPQDS LSAPSVASRF IDSHTPPLRP
     ILKKTASLGF CVTYVFFITS LIYPAICTNI ESLNKGSGSL WTTKFFIPLT TFLLYNFADL
     CGRQLTAWIQ VPGPNSKALP GFVLLRTCLI PLFVLCNYQP RVHLKTVVFQ SDVYPALLSS
     LLGLSNGYLS TLALLYGPKI VPRELAEATG VVMSFYVCLG LTLGSACSTL LVHLI
//
